ASU Biodesign Scientists Hope to Apply Direct-to-Consumer Model to Proteomics Testing

The researchers have launched a biotech firm, Healthtell, that aims to use immunosignaturing to develop diagnostics for a variety of indications and potentially enable ongoing monitoring of individuals via mailed-in serum samples.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.